Login to Your Account

'A lot of firsts,' as Korean firm Viromed advances gene therapy

By Haky Moon
Staff Writer

Friday, January 29, 2016

HONG KONG – With the successful completion of a phase II study in the U.S. for its flagship product, VM202, for the treatment of critical limb ischemia (CLI), South Korean biopharma Viromed Co. Ltd. is off to a good start this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription